| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ART.10148 |
| P8608 | Fatcat ID | release_qzwhydfrs5e6xflpebtpnyccge |
| P698 | PubMed publication ID | 11840435 |
| P2860 | cites work | The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 |
| Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group | Q28138338 | ||
| Evidence suggesting that a chronic disease self-management program can improve health status while reducing hospitalization: a randomized trial | Q28140220 | ||
| A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate | Q28295474 | ||
| A randomised double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis | Q28325989 | ||
| Synthetic D(-)penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen | Q28328917 | ||
| Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components | Q28343376 | ||
| The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses | Q29542806 | ||
| Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group | Q29616063 | ||
| Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study | Q29620671 | ||
| A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis | Q50132265 | ||
| Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. | Q50850177 | ||
| Measuring health status in arthritis. The arthritis impact measurement scales. | Q51270176 | ||
| Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. | Q52221782 | ||
| Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. | Q52225534 | ||
| A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. | Q52863944 | ||
| Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. | Q53793714 | ||
| The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. | Q53988786 | ||
| A double-blind controlled study comparing sulphasalazine with placebo in rheumatoid factor (RF)-negative rheumatoid arthritis. | Q53993832 | ||
| Measurement of patient outcome in arthritis | Q56879288 | ||
| Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis | Q57169679 | ||
| Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. | Q33178529 | ||
| Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group | Q33180020 | ||
| Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial | Q33362595 | ||
| Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial | Q33478118 | ||
| Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placebo | Q33553024 | ||
| Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study | Q33556920 | ||
| Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine | Q33564938 | ||
| The costs of rheumatoid arthritis | Q33568945 | ||
| Radiographic changes in early rheumatoid disease | Q33569899 | ||
| Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis | Q33570140 | ||
| Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications | Q33676719 | ||
| The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach | Q33710863 | ||
| Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy | Q33781852 | ||
| Economic burden of rheumatoid arthritis: a systematic review | Q33831406 | ||
| Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group | Q33885648 | ||
| Prognostic factors in early rheumatoid arthritis | Q34042716 | ||
| Outcomes of self-help education for patients with arthritis | Q34198626 | ||
| Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. | Q34327750 | ||
| Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. | Q34459461 | ||
| The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial | Q34646463 | ||
| Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial | Q34720605 | ||
| Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands | Q35549353 | ||
| Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis | Q35550470 | ||
| Rheumatoid arthritis. Pathophysiology and implications for therapy | Q38019708 | ||
| Adult and juvenile rheumatoid arthritis: current epidemiologic concepts | Q40319993 | ||
| Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: A retrospective study | Q40470276 | ||
| Second-line drug therapy for rheumatoid arthritis | Q40736923 | ||
| The role of social support with rheumatic disease | Q40827020 | ||
| The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials | Q40914450 | ||
| Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. An update from the International Kidney Biopsy Registry | Q41116423 | ||
| The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis | Q41200879 | ||
| An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline | Q41671791 | ||
| Surgical management of the rheumatoid hip. | Q41717916 | ||
| A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores | Q41736717 | ||
| Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group | Q41924053 | ||
| Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications | Q41930813 | ||
| Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis | Q41931766 | ||
| Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone | Q41932413 | ||
| A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis | Q41935381 | ||
| Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial | Q41936586 | ||
| Should disease-modifying agents be used in mild rheumatoid arthritis? | Q41941235 | ||
| Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis | Q41945874 | ||
| Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study | Q42549111 | ||
| Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months | Q42617960 | ||
| How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? | Q43626430 | ||
| Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment | Q46242303 | ||
| P433 | issue | 2 | |
| P921 | main subject | immunology | Q101929 |
| rheumatoid arthritis | Q187255 | ||
| rheumatology | Q327657 | ||
| P304 | page(s) | 328-346 | |
| P577 | publication date | 2002-02-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Guidelines for the management of rheumatoid arthritis: 2002 Update | |
| P478 | volume | 46 |
| Q95359372 | Q95359372 |
| Q38545293 | A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization |
| Q54965085 | A Novel Circulating miRNA-Based Model Predicts the Response to Tripterysium Glycosides Tablets: Moving Toward Model-Based Precision Medicine in Rheumatoid Arthritis. |
| Q38497739 | A Randomized Controlled Trial of the Cost-Effectiveness of Ultrasound-Guided Intraarticular Injection of Inflammatory Arthritis |
| Q36343561 | A Study Evaluating Adherence and Compliance of Anti-rheumatic Drugs in Women Suffering from Rheumatoid Arthritis |
| Q46986955 | A case of recurrent breast cancer with life-threatening multiple lung metastasis markedly responding to CMF as third-line chemotherapy |
| Q81972128 | A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis |
| Q51506928 | A cross-sectional study of diastolic dysfunction in rheumatoid arthritis and its association with disease activity. |
| Q39236507 | A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis |
| Q42685398 | A genome-wide screen of gene-gene interactions for rheumatoid arthritis susceptibility |
| Q39112806 | A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study). |
| Q44636715 | A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate |
| Q33921820 | A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active [...] |
| Q51630630 | A proposal of simple calculation (ERI calculator) to predict the early response to TNF-α blockers therapy in rheumatoid arthritis. |
| Q27309258 | A prospective pilot study to evaluate an animated home-based physical exercise program as a treatment option for patients with rheumatoid arthritis |
| Q46557700 | A qualitative study exploring community yoga practice in adults with rheumatoid arthritis |
| Q27309362 | A qualitative study of patients' perspectives on collaboration to support self-management in routine rheumatology consultations |
| Q27021435 | A systematic critical appraisal of non-pharmacological management of rheumatoid arthritis with Appraisal of Guidelines for Research and Evaluation II |
| Q38222186 | A systematic review into the effectiveness of hand exercise therapy in the treatment of rheumatoid arthritis |
| Q37160391 | A systematic review of infliximab in the treatment of early rheumatoid arthritis |
| Q35207886 | A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis |
| Q37672814 | Abatacept for the treatment of rheumatoid arthritis: A review |
| Q35907809 | Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis |
| Q37015967 | Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis |
| Q37175428 | Acid-sensing ion channel 3 expression in mouse knee joint afferents and effects of carrageenan-induced arthritis |
| Q49723275 | Activation status of peripheral blood neutrophils and the complement system in adult rheumatoid arthritis patients undergoing combined therapy with infliximab and methotrexate |
| Q35637990 | Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study |
| Q28282655 | Adalimumab for the treatment of rheumatoid arthritis |
| Q82887715 | Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis |
| Q36907691 | Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort |
| Q34156535 | Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature |
| Q35072852 | Advances in rheumatology: coxibs and beyond |
| Q21093257 | Advances in rheumatology: new targeted therapeutics |
| Q34706876 | Advances in the treatment of rheumatoid arthritis: old versus new therapies |
| Q43633174 | Age-related diagnostic utility of rheumatoid factor, anticyclic citrullinated peptide and antikeratin antibodies in Chinese patients with rheumatoid arthritis |
| Q47968567 | Alexithymia, depression, inflammation, and pain in patients with rheumatoid arthritis |
| Q36778521 | An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression |
| Q33813403 | An evaluation of the utility of routine laboratory monitoring of juvenile idiopathic arthritis (JIA) patients using non-steroidal anti-inflammatory drugs (NSAIDs): a retrospective review |
| Q36055449 | An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists |
| Q24241707 | Anakinra for rheumatoid arthritis |
| Q24243387 | Anakinra for rheumatoid arthritis |
| Q35709754 | Angiotensin-converting enzyme inhibitor therapy in patients with heart failure enrolled in a managed care organization: effect on costs and probability of hospitalization |
| Q47633995 | Annual costs of rheumatoid arthritis in Turkey |
| Q24816803 | Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis |
| Q36052572 | Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. |
| Q36776959 | Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. |
| Q36655144 | Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients |
| Q35194392 | Anticipating and treating opioid-associated adverse effects |
| Q33355906 | Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis |
| Q36622653 | Application of cellular gene therapy for rheumatoid arthritis |
| Q30426777 | Application of high frequency color Doppler ultrasound in the monitoring of rheumatoid arthritis treatment |
| Q35605514 | Are bone erosions detected by magnetic resonance imaging and ultrasonography true erosions? A comparison with computed tomography in rheumatoid arthritis metacarpophalangeal joints |
| Q36850809 | Arthritis and pain. Current approaches in the treatment of arthritic pain |
| Q36383132 | Association between PADI4 and rheumatoid arthritis: a meta-analysis |
| Q36725336 | Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study |
| Q24812290 | Association between the TNFRII 196R allele and diagnosis of rheumatoid arthritis. |
| Q46951195 | Association of anti-CCP positivity with serum ferritin and DAS-28. |
| Q34616332 | Association of the CD28/CTLA4/ICOS polymorphisms with susceptibility to rheumatoid arthritis |
| Q41648387 | Associations Between Patient Characteristics and the Amount of Arthritis Medication Information Patients Receive |
| Q36596894 | Atherogenic lipid profiles and its management in patients with rheumatoid arthritis |
| Q40064095 | Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction |
| Q37304347 | Autologous chondrocyte implantation for rheumatoid arthritis of the knee: a case report |
| Q33873699 | Autophagy induction and CHOP under-expression promotes survival of fibroblasts from rheumatoid arthritis patients under endoplasmic reticulum stress |
| Q28191932 | Balancing the gastrointestinal benefits and risks of nonselective NSAIDs |
| Q38647708 | Balneotherapy in rheumatoid arthritis-a systematic review |
| Q83762288 | Baseline anti-citrullinated peptide antibody (ACPA) titers and serum interleukin-6 (IL-6) levels possibly predict progression of bone destruction in early stages of rheumatoid arthritis (ERA) |
| Q53826993 | Baseline serum level of matrix metalloproteinase-3 as a biomarker of progressive joint damage in rheumatoid arthritis patients. |
| Q46704739 | Bleeding complications in patients on celecoxib and warfarin |
| Q50756971 | Body composition of rheumatoid arthritis patients in the City of Cape Town, South Africa. |
| Q36408376 | C-reactive protein, inflammatory conditions, and cardiovascular disease risk |
| Q37000103 | Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? |
| Q24813076 | Can magnetic resonance imaging differentiate undifferentiated arthritis? |
| Q34573121 | Can the painDETECT Questionnaire score and MRI help predict treatment outcome in rheumatoid arthritis: protocol for the Frederiksberg hospital's Rheumatoid Arthritis, pain assessment and Medical Evaluation (FRAME-cohort) study |
| Q34582722 | Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison |
| Q41998132 | Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). |
| Q41934162 | Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients |
| Q34584630 | Celecoxib: a review of its use in the management of arthritis and acute pain |
| Q33552879 | Cell-penetrating peptides released from thermosensitive nanoparticles suppress pro-inflammatory cytokine response by specifically targeting inflamed cartilage explants |
| Q35581451 | Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis |
| Q36763024 | Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population |
| Q39002210 | Characteristics of hand involvement in a comparative study of two early RA cohorts from the UK and China |
| Q40199980 | Characteristics of rheumatoid arthritis patients undergoing reverse shoulder arthroplasty |
| Q38206488 | Choosing Wisely: the American College of Rheumatology's Top 5 for pediatric rheumatology |
| Q48148502 | Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis. |
| Q35953570 | Cigarette smoking and radiographic progression in rheumatoid arthritis |
| Q45959202 | Classifying radiographic progression status in early rheumatoid arthritis patients using propensity scores to adjust for baseline differences. |
| Q37636900 | Clinical analysis of chinese patients with rheumatoid arthritis treated with leflunomide and methotrexate combined with different dosages of glucocorticoid |
| Q84135033 | Clinical guidelines: New guidelines on nondrug treatment in RA |
| Q26995307 | Clinical outcomes in psoriatic arthritis: A systematic literature review |
| Q36892770 | Clinical pharmacokinetics and use of infliximab |
| Q35636558 | Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology |
| Q37192026 | Clinical practice guidelines for the foot and ankle in rheumatoid arthritis: a critical appraisal. |
| Q37120248 | Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis |
| Q46982445 | Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole |
| Q33668201 | Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment |
| Q41858036 | Co-existence of acute myeloid leukemia with multilineage dysplasia and Epstein-Barr virus-associated T-cell lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report |
| Q46711323 | Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis |
| Q36897036 | Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs |
| Q42734907 | Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System |
| Q53125340 | Comparison of expectations of physicians and patients with rheumatoid arthritis for rheumatology clinic visits: a pilot, multicenter, international study. |
| Q39905110 | Comparison of osteoclast precursors in peripheral blood mononuclear cells from rheumatoid arthritis and osteoporosis patients |
| Q24630541 | Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study |
| Q24247348 | Comprehensive physiotherapy for rheumatoid arthritis |
| Q51255641 | Contribution of ethnic group and socioeconomic status to degree of disability in rheumatoid arthritis in Chilean patients. |
| Q34897214 | Conventional radiography requires a MRI-estimated bone volume loss of 20% to 30% to allow certain detection of bone erosions in rheumatoid arthritis metacarpophalangeal joints. |
| Q57169486 | Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis |
| Q43266399 | Cost effectiveness of leflunomide in the treatment of rheumatoid arthritis in Japan |
| Q79385062 | Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis |
| Q38013786 | Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model |
| Q83001629 | Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis |
| Q57658712 | Cost–effectiveness of tumor necrosis factor-α antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis |
| Q47228673 | Cultural adaptation, validity, reliability and responsiveness of the Swedish version of the effective musculoskeletal consumer scale (EC-17). |
| Q38035095 | Current considerations for the management of musculoskeletal pain in Asian countries: a special focus on cyclooxygenase-2 inhibitors and non-steroid anti-inflammation drugs |
| Q38033650 | Current treatments of rheumatoid arthritis: from the 'NinJa' registry |
| Q35973747 | Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destruction |
| Q37609406 | Depression and health-related quality of life in patients with rheumatoid arthritis. |
| Q38981346 | Depressive symptoms predict future simple disease activity index scores and simple disease activity index remission in a prospective cohort of patients with early inflammatory polyarthritis |
| Q57752989 | Detection of bone erosions in early rheumatoid arthritis: 3D ultrasonography versus computed tomography |
| Q36641552 | Detection of bone erosions in rheumatoid arthritis wrist joints with magnetic resonance imaging, computed tomography and radiography |
| Q33631273 | Determining early referral criteria for patients with suspected inflammatory arthritis presenting to primary care physicians: a cross-sectional study. |
| Q40149345 | Developing multidisciplinary guidelines for the management of early rheumatoid arthritis |
| Q33554376 | Development of a framework for reporting health service models for managing rheumatoid arthritis |
| Q35808002 | Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis |
| Q42677290 | Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER |
| Q57169507 | Disease activity and functional changes of RA patients receiving different DMARDs in clinical practice |
| Q36592626 | Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future |
| Q53130911 | Disease-specific knowledge and clinical skills required by community-based physiotherapists to co-manage patients with rheumatoid arthritis. |
| Q37401906 | Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study |
| Q33708846 | Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? |
| Q38039360 | Do dynamic strengthening and aerobic capacity exercises reduce pain and improve functional outcomes and strength in people with established rheumatoid arthritis? |
| Q37592849 | Do specialized centers and specialists produce better outcomes for patients with chronic diseases than primary care generalists? A systematic review |
| Q27023091 | Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis -- focus on subcutaneous tocilizumab |
| Q24240321 | Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis |
| Q31119321 | EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). |
| Q34110066 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs |
| Q36563395 | Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials |
| Q35554539 | Effect of Curcuma zedoaria Rosc root extracts on behavioral and radiology changes in arthritic rats |
| Q35823650 | Effective use of TNF antagonists |
| Q34012929 | Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). |
| Q33932391 | Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study |
| Q47862287 | Effects of home-based exercise program on the functional status and the quality of life in patients with rheumatoid arthritis: 1-year follow-up study |
| Q82906930 | Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity |
| Q46013134 | Effects of low-dose mizoribine pulse therapy in combination with methotrexate in rheumatoid arthritis patients with an insufficient response to methotrexate. |
| Q41534957 | Effects of low-dose tacrolimus therapy in combination with methotrexate in patients with methotrexate-refractory rheumatoid arthritis. |
| Q35520129 | Efficacy & safety evaluation of Ayurvedic treatment (Ashwagandha powder & Sidh Makardhwaj) in rheumatoid arthritis patients: a pilot prospective study. |
| Q98772480 | Efficacy and Safety of Opinercept Tumor Necrosis Factor Inhibitor Therapy for Drug-Refractory Rheumatoid Arthritis: A Randomized Clinical Trial |
| Q35554130 | Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed |
| Q43166171 | Efficacy and safety of celecoxib in the treatment of acute pain due to ankle sprain in a Latin American and Middle Eastern population. |
| Q39320502 | Efficacy and safety of etoricoxib in the treatment of osteoarthritis |
| Q43172639 | Efficacy and safety of ketoprofen patch in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study |
| Q39169130 | Efficacy and safety of point-of-care ultrasound-guided intra-articular corticosteroid joint injections in patients with haemophilic arthropathy |
| Q35020811 | Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. |
| Q39304368 | Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial |
| Q34553523 | Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis |
| Q36062038 | Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis |
| Q24806495 | Encouraging physician appropriate prescribing of non-steroidal anti-inflammatory therapies: protocol of a randomized controlled trial [ISRCTN43532635]. |
| Q46699120 | End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome |
| Q42639889 | Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis |
| Q40813632 | Epidemiology and Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population |
| Q33844552 | Establishing key components of yoga interventions for musculoskeletal conditions: a Delphi survey |
| Q53250210 | Etanercept in severe active rheumatoid arthritis: first Australian experience. |
| Q35938511 | Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis |
| Q36830130 | Etanercept: a review of its use in the management of rheumatoid arthritis |
| Q34991484 | Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis |
| Q35166773 | Etoricoxib for arthritis and pain management |
| Q35190112 | Evaluation and management of psoriatic arthritis: the role of biologic therapy |
| Q36823811 | Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis |
| Q43270613 | Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis |
| Q50623527 | Exercises to improve function of the rheumatoid hand (SARAH): a randomised controlled trial. |
| Q33537396 | Exploring Tai Chi in rheumatoid arthritis: a quantitative and qualitative study |
| Q39865550 | Exploring the public health impact of an intensive exercise program for patients with rheumatoid arthritis: a dissemination and implementation study |
| Q36896228 | Extracts of Tripterygium wilfordii Hook F in the Treatment of Rheumatoid Arthritis: A Systemic Review and Meta-Analysis of Randomised Controlled Trials |
| Q40479806 | Factors affecting well-being in adults recently diagnosed with rheumatoid arthritis. |
| Q48503161 | Factors influencing quality of life (QOL) for Korean patients with rheumatoid arthritis (RA). |
| Q26783178 | Fcγ and Complement Receptors and Complement Proteins in Neutrophil Activation in Rheumatoid Arthritis: Contribution to Pathogenesis and Progression and Modulation by Natural Products |
| Q35211365 | Frequency of radiologic procedures in patients with rheumatoid arthritis. |
| Q46907611 | Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis |
| Q36857013 | Glenohumeral joint injections: a review |
| Q36023494 | Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study |
| Q37684575 | Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis |
| Q37382183 | Green tea and exercise interventions as nondrug remedies in geriatric patients with rheumatoid arthritis |
| Q43675571 | Guidelines for the drug treatment of rheumatoid arthritis |
| Q38839530 | Hand exercises for patients with rheumatoid arthritis: an extended follow-up of the SARAH randomised controlled trial. |
| Q50157070 | Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme? |
| Q46879529 | Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial |
| Q39317364 | Health Professionals' Perceptions of the Effects of Exercise on Joint Health in Rheumatoid Arthritis Patients. |
| Q35637506 | Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies |
| Q24236611 | Herbal therapy for treating rheumatoid arthritis |
| Q37346732 | Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis |
| Q37870212 | How should morning function in rheumatoid arthritis be assessed? Bibliographic study of current assessment |
| Q37158219 | Hypertension in rheumatoid arthritis. |
| Q37734731 | Identifying and assessing benefit-risk in primary care--a family physician's perspective |
| Q38386610 | Iguratimod for the treatment of rheumatoid arthritis in Japan |
| Q47926149 | Imaging in rheumatoid arthritis – why MRI and ultrasonography can no longer be ignored |
| Q35581131 | Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases |
| Q64917344 | Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data. |
| Q28071550 | Implications of analgesics use in osteoporotic-related pain treatment: focus on opioids |
| Q39057277 | Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap. |
| Q30585733 | Improvement in wrist pain with ultrasound-guided glucocorticoid injections: a meta-analysis of individual patient data |
| Q36784125 | Improving treatment adherence in patients with rheumatoid arthritis: what are the options? |
| Q80141033 | Increased prevalence of anti-third generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome |
| Q36731722 | Increased responsiveness to toll-like receptor 4 stimulation in peripheral blood mononuclear cells from patients with recent onset rheumatoid arthritis |
| Q35152581 | Increased risk of depression in patients with rheumatoid arthritis: a seven-year population-based cohort study |
| Q37275656 | Induction of remission in rheumatoid arthritis: criteria and opportunities |
| Q38335718 | Infection risk associated with anti-TNF-α agents: a review |
| Q35632732 | Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis |
| Q36286223 | Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis |
| Q47280323 | Influence of foot orthoses on plantar pressures, foot pain and walking ability of rheumatoid arthritis patients--a randomised controlled study |
| Q82076763 | Inhibiting interleukin-6 in rheumatoid arthritis |
| Q34019267 | Initiation of rheumatoid arthritis treatments and the risk of serious infections |
| Q36204088 | Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) |
| Q36100671 | International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review |
| Q41534964 | Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis |
| Q39362528 | Kudo total elbow arthroplasty in rheumatoid arthritis. Clinical and radiological results. |
| Q82470976 | Lag time between onset of symptoms and diagnosis in Venezuelan patients with rheumatoid arthritis |
| Q24613130 | Laser in situ keratomileusis in patients with collagen vascular disease: a review of the literature |
| Q36484975 | Leflunomide and warfarin interaction: case report and review of the literature |
| Q45954946 | Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment. |
| Q41946145 | Leflunomide/chloroquin combination therapy in rheumatoid arthritis: a pilot study |
| Q36946654 | Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial |
| Q90193988 | Linkage of Periodontitis and Rheumatoid Arthritis: Current Evidence and Potential Biological Interactions |
| Q34153033 | Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis |
| Q45929015 | Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients. |
| Q33907217 | Looking through the 'window of opportunity': is there a new paradigm of podiatry care on the horizon in early rheumatoid arthritis? |
| Q50545459 | Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database. |
| Q35637890 | Low-cost, low-field dedicated extremity magnetic resonance imaging in early rheumatoid arthritis: a 1-year follow-up study |
| Q39896794 | Lower Healthy Eating Index-2005 dietary quality scores in older women with rheumatoid arthritis v. healthy controls |
| Q45038809 | Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients |
| Q36295221 | Management issues with elderly-onset rheumatoid arthritis: an update |
| Q38440728 | Management of Children with Juvenile Idiopathic Arthritis |
| Q37173212 | Management of chronic nonmalignant pain with nonsteroidal antiinflammatory drugs. Joint opinion statement of the Ambulatory Care, Cardiology, and Pain and Palliative Care Practice and Research Networks of the American College of Clinical Pharmacy |
| Q36055455 | Management of sight-threatening uveitis: new therapeutic options. |
| Q38255960 | Managing chronic pain in adults with haemophilia: current status and call to action |
| Q38214363 | Marital quality and self-efficacy: influence on disease management among individuals with rheumatoid arthritis |
| Q38072667 | Maximizing early treatment with biologics in patients with rheumatoid arthritis: the ultimate breakthrough in joints preservation |
| Q35799572 | Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics |
| Q36067667 | Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors |
| Q39328144 | Mediating Effect of Changes in Hand Impairments on Hand Function in Patients With Rheumatoid Arthritis: Exploring the Mechanisms of an Effective Exercise Program. |
| Q36588856 | Medical therapy: where are we now? |
| Q38599556 | Medication nonadherence in Korean patients with rheumatoid arthritis: the importance of belief about medication and illness perception |
| Q36107389 | Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis |
| Q46879855 | Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease |
| Q24200564 | Methotrexate for ankylosing spondylitis |
| Q24244003 | Methotrexate for ankylosing spondylitis |
| Q24248035 | Methotrexate for ankylosing spondylitis |
| Q36986025 | Methotrexate in dermatology |
| Q35182959 | Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives? |
| Q35636960 | Methotrexate modulates the kinetics of adenosine in humans in vivo |
| Q45184315 | Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands |
| Q38014684 | Molecular characterization of rheumatoid arthritis with magnetic resonance imaging. |
| Q24684208 | Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis |
| Q44229904 | Monitoring and assessing the safety of disease-modifying antirheumatic drugs: a West Midlands experience |
| Q48304448 | Morning stiffness and other patient-reported outcomes of rheumatoid arthritis in clinical practice |
| Q42971950 | Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials |
| Q73774973 | New radiographic bone erosions in the wrists of patients with rheumatoid arthritis are detectable with magnetic resonance imaging a median of two years earlier |
| Q37986562 | Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole. |
| Q36593635 | Nonpharmacological treatment of pain in rheumatic diseases and other musculoskeletal pain conditions |
| Q82491231 | Observational Cross-Sectional Study Revealing Less Aggressive Treatment in Japanese Elderly Than Nonelderly Patients With Rheumatoid Arthritis |
| Q80483048 | Observational study of a patient and doctor directed pre-referral questionnaire for an early arthritis clinic |
| Q34559803 | Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? |
| Q24235173 | Opioid therapy for treating rheumatoid arthritis pain |
| Q24236170 | Opioid therapy for treating rheumatoid arthritis pain |
| Q53698245 | Osseous changes in the temporomandibular joint in rheumatoid arthritis: A cone-beam computed tomography study. |
| Q57169339 | Ottawa Panel evidence-based clinical practice guidelines for patient education in the management of Rheumatoid Arthritis (RA) |
| Q80363563 | Pathway to independence: physical therapy for patients with rheumatoid arthritis |
| Q33803037 | Patient benefit-risk in arthritis--a rheumatologist's perspective |
| Q51726032 | Patient demographics and disease variables correlate with distinct cytokine patterns in mitogen-stimulated peripheral blood mononuclear cells from rheumatoid arthritis patients. |
| Q47808321 | Patient preferences for psychological support in inflammatory arthritis: a multicentre survey |
| Q35636868 | Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial |
| Q36447439 | Patient's Knowledge and Perception Towards the use of Non-steroidal Anti-Inflammatory Drugs in Rheumatology Clinic Northern Malaysia |
| Q40348896 | Patient-reported outcomes as assessment tools and predictors of long-term prognosis: a 7-year follow-up study of patients with rheumatoid arthritis |
| Q33451953 | Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank |
| Q34022346 | Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study |
| Q34379235 | Patterns of disease-modifying antirheumatic drug use in rheumatoid arthritis patients after 2002: a systematic review |
| Q43165952 | Payers Have Biologic Alternative for Patients With Moderate to Severe Rheumatoid Arthritis Who Do Not Respond to Other DMARD Therapies. |
| Q35702552 | Perceptions of physical activity engagement among adults with rheumatoid arthritis and rheumatologists |
| Q54565569 | Pharmacogenetic study of methylenetetrahydrofolate reductase and thymidylate synthase in Japanese and assessment of ethnic and gender differences. |
| Q45912075 | Physical therapists' management of rheumatoid arthritis: results of a Dutch survey. |
| Q38719056 | Plasma levels of D-dimer in a 5-year-old girl with systemic juvenile idiopathic arthritis: A case report and literature review |
| Q35154359 | Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis |
| Q28191928 | Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs |
| Q37665060 | Predictor of Hand Radiological Progression in Patients With Rheumatoid Arthritis Receiving TNF Antagonist Therapy by Change in Grayscale Synovitis-A Preliminary Study |
| Q35681911 | Predictors of Medication Adherence in Patients with Rheumatoid Arthritis |
| Q37028263 | Predictors of perceived higher quality patient-provider communication in patients with rheumatoid arthritis |
| Q33955222 | Predictors of stopping and starting disease-modifying antirheumatic drugs for rheumatoid arthritis |
| Q39958615 | Predictors of the use of physical therapy services among patients with rheumatoid arthritis. |
| Q38183425 | Prefilled devices for parenteral applications |
| Q79603683 | Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone |
| Q36093378 | Preserved skeletal muscle protein anabolic response to acute exercise and protein intake in well-treated rheumatoid arthritis patients |
| Q37222338 | Pro-apoptotic effect of nonsteroidal anti-inflammatory drugs on synovial fibroblasts |
| Q42603691 | Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids |
| Q33503888 | Protective effect of geranylgeranylacetone, an inducer of heat shock protein 70, against drug-induced lung injury/fibrosis in an animal model |
| Q30235888 | Psoriasis and comorbid diseases: Implications for management |
| Q37016098 | Psychologic interventions and lifestyle modifications for arthritis pain management |
| Q84866028 | Pulmonary tuberculosis and tuberculous arthritis of knee joint associated with rheumatoid arthritis treated with anti-tumor necrosis factor (TNF)-alpha medication: a case report |
| Q35780344 | Pursuit of optimal outcomes in rheumatoid arthritis |
| Q33956726 | Quality appraisal of clinical practice guidelines on the use of physiotherapy in rheumatoid arthritis: a systematic review. |
| Q52332581 | Quality of Care in Rheumatoid Disease from the Clinician Perspective: A Modified Delphi Panel Approach. |
| Q37269344 | Quality-of-life assessment in rheumatoid arthritis |
| Q64064767 | RNA sequencing of mesenchymal stem cells reveals a blocking of differentiation and immunomodulatory activities under inflammatory conditions in rheumatoid arthritis patients |
| Q35638288 | Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis |
| Q33792588 | Randomised controlled trial examining the effect of exercise in people with rheumatoid arthritis taking anti-TNFα therapy medication |
| Q47262616 | Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate |
| Q35212433 | Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans |
| Q36485737 | Recent paradigm shifts in the diagnosis and treatment of rheumatoid arthritis |
| Q53659345 | Recent trends in use of nonbiologic DMARDs and evaluation of their continuation rates in single and dual combination therapies in rheumatoid arthritis patients in Japan. |
| Q36713901 | Recommendations and the state of the evidence for physical activity interventions for adults with rheumatoid arthritis: 2007 to present |
| Q28080677 | Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab |
| Q28710161 | Regional and temporal variation in the treatment of rheumatoid arthritis across the UK: a descriptive register-based cohort study |
| Q44361092 | Regulation of nitric oxide production in osteoarthritic and rheumatoid cartilage. Role of endogenous IL-1 inhibitors |
| Q55513283 | Relationship between beliefs about medicines, adherence to treatment, and disease activity in patients with rheumatoid arthritis under subcutaneous anti-TNFα therapy. |
| Q36942978 | Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis |
| Q44973872 | Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study |
| Q38831661 | Rethinking chronic pain in a primary care setting |
| Q55263498 | Retinal Vessel Diameters and Physical Activity in Patients With Mild to Moderate Rheumatic Disease Without Cardiovascular Comorbidities. |
| Q36517701 | Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2) |
| Q54571788 | Retrospective study of salazosulfapyridine in eight patients with rheumatoid arthritis on hemodialysis. |
| Q73369641 | Reumacon (CPH82) showed similar x‐ray progression and clinical effects as methotrexate in a two year comparative study on patients with early rheumatoid arthritis |
| Q57735588 | Rheumatoid Arthritis Associated With Pemphigus Foliaceus in a Patient Not Taking Penicillamine |
| Q53409840 | Rheumatoid Arthritis of the Hand: Monitoring with a Simplified MR Imaging Scoring Method—Preliminary Assessment |
| Q36973563 | Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment |
| Q33307666 | Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. |
| Q37386672 | Rheumatoid arthritis: Guidelines for the management of RA: breadth versus depth |
| Q36160669 | Rheumatoid arthritis: an overview of new and emerging therapies |
| Q35757007 | Rheumatoid arthritis: refractory to infliximab, a tumor necrosis factor inhibitor |
| Q88052058 | Risk Factors for Transfusions Following Total Joint Arthroplasty in Patients With Rheumatoid Arthritis |
| Q43281540 | Risk factors for the development of gastric mucosal lesions in rheumatoid arthritis patients receiving long-term nonsteroidal anti-inflammatory drug therapy and the efficacy of famotidine obtained from the FORCE study |
| Q36600810 | Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. |
| Q34497135 | Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy |
| Q35999197 | Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study |
| Q35999139 | Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis |
| Q42628958 | Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial |
| Q35194346 | Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis |
| Q46572785 | Safety profile of tacrolimus in patients with rheumatoid arthritis |
| Q37305184 | Sarcopenia in women with rheumatoid arthritis |
| Q40875239 | Second-line therapy with biological drugs in rheumatoid arthritis patients in German rheumatologist practices: a retrospective database analysis |
| Q36718318 | Self Management Behaviors in Rheumatoid Arthritis Patients and Associated Factors in Tehran 2013. |
| Q36927546 | Septic arthritis in Iceland 1990-2002: increasing incidence due to iatrogenic infections |
| Q94596628 | Serum Neuropeptide Y Levels Are Associated with TNF-α Levels and Disease Activity in Rheumatoid Arthritis |
| Q47615878 | Serum levels of anti-cyclic citrullinated peptide antibodies are associated with a beneficial response to traditional herbal medicine (Kampo) in rheumatoid arthritis |
| Q41945617 | Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease |
| Q51804775 | Significance of anti-CCP antibodies in modification of 1987 ACR classification criteria in diagnosis of rheumatoid arthritis. |
| Q55107496 | Spironolactone (an adjuvant therapy) in rheumatoid arthritis: a case control study. |
| Q35902007 | Standards of medical treatment and nutrition in Crohn's disease |
| Q53663109 | State of the art of ultrasound in the assessment of psoriasis and psoriatic arthritis. |
| Q58851305 | Stereoselective disposition of fenoprofen in plasma and synovial fluid of patients with rheumathoid arthritis |
| Q34486680 | Strengthening and stretching for rheumatoid arthritis of the hand (SARAH): design of a randomised controlled trial of a hand and upper limb exercise intervention--ISRCTN89936343. |
| Q35610255 | Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database |
| Q24244129 | Sulfasalazine for ankylosing spondylitis |
| Q24248125 | Sulfasalazine for ankylosing spondylitis |
| Q36237544 | Sulfasalazine: a review of its use in the management of rheumatoid arthritis |
| Q38253590 | Systematic review and meta-analysis of effects of foot orthoses on pain and disability in rheumatoid arthritis patients. |
| Q33240856 | Systematic review of measures and their concepts used in published studies focusing on the treatment of acute inflammatory arthritis |
| Q46036804 | Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. |
| Q36126516 | Tacrolimus: in patients with rheumatoid arthritis |
| Q84961159 | The Complexity of the Treatment: The Decision-Making Process Among Women With Rheumatoid Arthritis |
| Q35627227 | The Trends of DMARDS prescribed in Rheumatoid Arthritis Patients in Malaysia |
| Q77791853 | The association between yoga use, physical function, and employment in adults with rheumatoid arthritis |
| Q46609153 | The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database |
| Q28219195 | The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks |
| Q34529734 | The development and future of reconstructive and microvascular surgery of the hand |
| Q34360383 | The effect of conditioning exercise on the health status and pain in patients with rheumatoid arthritis: a randomized controlled clinical trial |
| Q90704178 | The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: results from a retrospective cohort study |
| Q47298646 | The extraarticular symptoms influence ACR response in the treatment of rheumatoid arthritis with biomedicine: a single-blind, randomized, controlled, multicenter trial in 194 patients |
| Q35810276 | The future of rheumatoid arthritis and hand surgery - combining evolutionary pharmacology and surgical technique |
| Q37251489 | The impact of rheumatoid arthritis and biologics on employers and payers. |
| Q45187063 | The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study |
| Q79141725 | The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis |
| Q27863372 | The interrelation of glutathione reductase, catalase, glutathione peroxidase, superoxide dismutase, and glucose-6-phosphate in the pathogenesis of rheumatoid arthritis |
| Q34326675 | The management of chronic pain in important patient subgroups |
| Q53441672 | The outcomes and cost-effectiveness of intraarticular injection of the rheumatoid knee. |
| Q36939711 | The role of nitric oxide in osteoarthritis |
| Q35149318 | The role of opioid analgesics in rheumatoid disease in the elderly population |
| Q38672339 | The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis. |
| Q42624577 | The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis |
| Q79721915 | The significance of platelet activation in rheumatoid arthritis |
| Q39723371 | The suitability of yoga as a potential therapeutic intervention for rheumatoid arthritis: a focus group approach |
| Q33968336 | The unequal burden of pain: confronting racial and ethnic disparities in pain. |
| Q37633537 | Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists |
| Q33976382 | Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial |
| Q47732498 | Tight control is important in patients with rheumatoid arthritis treated with an anti-tumor necrosis factor biological agent: prospective study of 91 cases who used a biological agent for more than 1 year |
| Q33432572 | Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor |
| Q37358242 | Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis |
| Q42143758 | Total knee arthroplasty in rheumatoid arthritis |
| Q47650717 | Traditional Chinese medicine versus western medicine as used in China in the management of rheumatoid arthritis: a randomized, single-blind, 24-week study |
| Q56060521 | Treatment of rheumatoid arthritis |
| Q34480974 | Trends of rheumatoid arthritis monitorization in Romania |
| Q36076386 | Tripterygium wilfordii Hook F versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: a systematic review and network meta-analysis |
| Q33328963 | Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety |
| Q44800317 | Tumor necrosis factor receptor II gene polymorphism and severity of rheumatoid arthritis |
| Q47888590 | Tumor necrosis factor-α inhibits chondrogenic differentiation of synovial fibroblasts through p38 mitogen activating protein kinase pathways |
| Q83577942 | USPIO-enhanced magnetic resonance imaging of the knee in asymptomatic volunteers |
| Q35070450 | Understanding emerging treatment paradigms in rheumatoid arthritis |
| Q36165321 | Unmet needs in rheumatoid arthritis |
| Q37033874 | Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis |
| Q35579232 | Use and misuse of corticosteroids |
| Q36182373 | Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population |
| Q36446926 | Use of disease-modifying antirheumatic drugs during pregnancy and risk of preeclampsia |
| Q35962028 | Use of macrolides and tetracyclines for chronic inflammatory diseases |
| Q57488699 | Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review protocol |
| Q36526969 | Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study |
| Q34557067 | Valdecoxib for the management of chronic and acute pain |
| Q28168735 | Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain |
| Q37723293 | Vascular function and inflammation in rheumatoid arthritis: the role of physical activity |
| Q34996190 | Weekly low-dose methotrexate for reduction of Global Initiative for Asthma Step 5 treatment in severe refractory asthma: study protocol for a randomized controlled trial |
| Q84396532 | When should we use parenteral methotrexate? |
| Q41611372 | Will Chinese external therapy with compound Tripterygium wilfordii hook F gel safely control disease activity in patients with rheumatoid arthritis: design of a double-blinded randomized controlled trial. |
| Q37588725 | Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'? |
| Q34518705 | Yoga for arthritis: a scoping review. |
| Q47719823 | Yoga for the management of pain and sleep in rheumatoid arthritis: a pilot randomized controlled trial. |
| Q35812056 | Yoga in Sedentary Adults with Arthritis: Effects of a Randomized Controlled Pragmatic Trial |
| Q35556790 | Yoga in rheumatic diseases |
| Q81241778 | [Current status of ambulatory rheumatologic health care in Germany. Structure of health care and range of services] |
| Q79192816 | [Effectiveness and safety of adalimumab and etanercept for rheumatoid arthritis in a third-level hospital] |
| Q52903653 | [How closely does rheumatology treatment follow the guidelines?: ambition and reality]. |
| Q80379439 | [Internist's therapy of rheumatoid arthritis] |
| Q83739191 | [Physical activity for prevention and therapy of internal diseases in the elderly] |
| Q52887770 | [Physical medicine in hospital. Minimum standards in a physical medical department in acute inpatient areas in rheumatology]. |
| Q52938817 | [Prescription of glucocorticoids by rheumatologists in patients with rheumatoid arthritis in Germany]. |
| Q84600331 | [Reduction in time until first treatment with disease modifying treatment in patients with rheumatoid arthritis] |
| Q52895477 | [Therapeutic strategies in rheumatoid arthritis]. |
Search more.